Journal article icon

Journal article

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

Abstract:

BACKGROUND: Ankylosing spondylitis is a chronic immune-mediated inflammatory disease characterised by spinal inflammation, progressive spinal rigidity, and peripheral arthritis. Interleukin 17 (IL-17) is thought to be a key inflammatory cytokine in the development of ankylosing spondylitis, the prototypical form of spondyloarthritis. We assessed the efficacy and safety of the anti-IL-17A monoclonal antibody secukinumab in treating patients with active ankylosing spondylitis. METHODS: We did a...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Baraliakos, X More by this author
Expand authors...
Journal:
Lancet
Volume:
382
Issue:
9906
Pages:
1705-1713
Publication date:
2013-11-05
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
URN:
uuid:7fcf404a-b42d-47f3-a4a6-1e954015f0b1
Source identifiers:
429695
Local pid:
pubs:429695

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP